2026 Q2 -tulosraportti
1 päivä sitten
‧32 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 20.8. | ||
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·48 min sittenDNB Carnegie's comment on Q2 2026: "Validation trial on track; KDIGO next catalyst – H1 review H1 earnings missed our forecasts as effects from the product recall were above our expectations, but we focus on the ProNephro US adult validation study, which we see as on track for a data readout in H2 2027. Fair value range of DKK0.5–3.0 per share reiterated. H1 review – solid execution and estimate changes. H1 sales were ~3% below our forecast (~14% above adjusted for the DKK2.8m negative impact from the product recall). In our view, this suggests a solid underlying trend in NGAL sales. Reported EBIT was DKK16m including effects from the sale of the antibodies business, offsetting negative effects from the recall. Full- year guidance was maintained but we cut our 2026e adj. EPS by ~15% due to higher opex, while raising 2027–28e by 5–6% on higher gross margin assumptions, driven by sales mix. Adult US ProNephro validation trial on track. BioPorto and the FDA aligned on the US adult validation study design earlier this year, expanding the study size to ~900 patients (~500 in the cut-off study). The first US clinical site was activated on 18 August. Thus, we believe the clinical trial (NCT07751913) remains well on track with expected readout in H2 2027. KDIGO guidelines likely the next catalyst. We expect a decision on KDIGO guidelines for NGAL biomarker tests as early as Q4 2026. Based on KDIGO’s public acute kidney injury (AKI) review, we still consider inclusion as likely, which in our view would provide validation of ProNephro and support broader clinical adoption. ProNephro is already FDA approved for paediatric use, CE-marked internationally, and globally available for RSUO, while we expect adult FDA approval in 2027. For the adult indication alone, we apply a 90% probability of approval and forecast a 27.9% CAGR (2028–45e), with a risk-adjusted NPV of DKK1.8 per share. Fair value range of DKK0.5–3.0 per share reiterated, based on a risk-adjusted SOTP NPV (16.5% WACC, 1.4x beta and 5% liquidity premium): the upper end reflects an additional 10% annual revenue growth and 1% annual EBITDA margin expansion from our forecasts over 2026– 45; the lower end assumes no FDA approval of ProNephro for adults.
·21 t sittenWatch or rewatch today's Webcast. https://www.inderes.dk/videos/bioporto-praesentation-af-h1-2026-resultaterYesterday we received news that Bioporto has already gained 54 new customers. Based on what CB said, he believed that the remaining 11 hospitals to be used for research were to be found among these 54 hospitals. It is a question of whether they can agree on the conditions for the hospitals to participate in the research. This is good news, because now there is a chance that they can start the research itself quickly. Bioporto received fast track status last time when the children's test was to be approved, and I hope that Bioporto will apply for it this time too, and get it. Because one of the advantages of this status is that when the FDA finally has to approve the test, it will at most only take 6 months; if one does not have any status, this process will take 10 months. Even better if it is Breakthrough Therapy, but it is rare for this status to be granted.
·23 t sittenI think the financial report - really! - holds the course. There has been a rather large product recall. That surprises me based on the following: - Why is the production control not in order? - Why do they produce in such large batches? With a price of 3 million: Do they only produce 8-10 times a year?! That is stupid!!!! I found it difficult to understand today's announcement based on the formulations in the financial report, and I haven't "picked up" the information either. 3D neither, and that says something! BioPorto is in a positive development, but they really need to be careful not to return to the PME-tiden. This financial report is ACCEPTED. But the grade is 4! The communication is simply not good enough! I hope they learn from it. Regards. Bagerbrød (who has kept his shares).Bagerbrød, now I have seen the webcast and I believe that I can tell you why they have started to have large batches. The reason is simple, because they have gained many customers, and therefore they must be able to cover the demand. Regarding the fact that they themselves found out that there are errors in their production so early, is actually also a success. Because it shows that their sample extractions and quality checks also work. As well as the staff at Bioporto who have these tasks, take their job seriously and they are good at it. I have worked in the production department at Novo Nordisk. With quality and production.- ·1 päivä sittenBioporte is weighed down by kidney test recall even though sales are growing We will probably get more information about that later today at 14:00 when there is a webcast https://www.nordnet.dk/markedet/nyheder/9133ec5e-5820-4d73-9b90-90768671459e
- ·1 päivä sittenIn 12 min, 332 kr. has been traded. I wonder if everyone is sitting ready and waiting for the financial report tonight? It's unsettling that a recall of +30 % of quarterly revenue doesn't give rise to a single critical remark.I am on bioporto's mailing list and I have not received news about that recall or seen news about it elsewhere. But I think investment-trade must be a trusted employee and insider since he is the only one who has received the news about it.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
1 päivä sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·48 min sittenDNB Carnegie's comment on Q2 2026: "Validation trial on track; KDIGO next catalyst – H1 review H1 earnings missed our forecasts as effects from the product recall were above our expectations, but we focus on the ProNephro US adult validation study, which we see as on track for a data readout in H2 2027. Fair value range of DKK0.5–3.0 per share reiterated. H1 review – solid execution and estimate changes. H1 sales were ~3% below our forecast (~14% above adjusted for the DKK2.8m negative impact from the product recall). In our view, this suggests a solid underlying trend in NGAL sales. Reported EBIT was DKK16m including effects from the sale of the antibodies business, offsetting negative effects from the recall. Full- year guidance was maintained but we cut our 2026e adj. EPS by ~15% due to higher opex, while raising 2027–28e by 5–6% on higher gross margin assumptions, driven by sales mix. Adult US ProNephro validation trial on track. BioPorto and the FDA aligned on the US adult validation study design earlier this year, expanding the study size to ~900 patients (~500 in the cut-off study). The first US clinical site was activated on 18 August. Thus, we believe the clinical trial (NCT07751913) remains well on track with expected readout in H2 2027. KDIGO guidelines likely the next catalyst. We expect a decision on KDIGO guidelines for NGAL biomarker tests as early as Q4 2026. Based on KDIGO’s public acute kidney injury (AKI) review, we still consider inclusion as likely, which in our view would provide validation of ProNephro and support broader clinical adoption. ProNephro is already FDA approved for paediatric use, CE-marked internationally, and globally available for RSUO, while we expect adult FDA approval in 2027. For the adult indication alone, we apply a 90% probability of approval and forecast a 27.9% CAGR (2028–45e), with a risk-adjusted NPV of DKK1.8 per share. Fair value range of DKK0.5–3.0 per share reiterated, based on a risk-adjusted SOTP NPV (16.5% WACC, 1.4x beta and 5% liquidity premium): the upper end reflects an additional 10% annual revenue growth and 1% annual EBITDA margin expansion from our forecasts over 2026– 45; the lower end assumes no FDA approval of ProNephro for adults.
- ·21 t sittenWatch or rewatch today's Webcast. https://www.inderes.dk/videos/bioporto-praesentation-af-h1-2026-resultaterYesterday we received news that Bioporto has already gained 54 new customers. Based on what CB said, he believed that the remaining 11 hospitals to be used for research were to be found among these 54 hospitals. It is a question of whether they can agree on the conditions for the hospitals to participate in the research. This is good news, because now there is a chance that they can start the research itself quickly. Bioporto received fast track status last time when the children's test was to be approved, and I hope that Bioporto will apply for it this time too, and get it. Because one of the advantages of this status is that when the FDA finally has to approve the test, it will at most only take 6 months; if one does not have any status, this process will take 10 months. Even better if it is Breakthrough Therapy, but it is rare for this status to be granted.
- ·23 t sittenI think the financial report - really! - holds the course. There has been a rather large product recall. That surprises me based on the following: - Why is the production control not in order? - Why do they produce in such large batches? With a price of 3 million: Do they only produce 8-10 times a year?! That is stupid!!!! I found it difficult to understand today's announcement based on the formulations in the financial report, and I haven't "picked up" the information either. 3D neither, and that says something! BioPorto is in a positive development, but they really need to be careful not to return to the PME-tiden. This financial report is ACCEPTED. But the grade is 4! The communication is simply not good enough! I hope they learn from it. Regards. Bagerbrød (who has kept his shares).Bagerbrød, now I have seen the webcast and I believe that I can tell you why they have started to have large batches. The reason is simple, because they have gained many customers, and therefore they must be able to cover the demand. Regarding the fact that they themselves found out that there are errors in their production so early, is actually also a success. Because it shows that their sample extractions and quality checks also work. As well as the staff at Bioporto who have these tasks, take their job seriously and they are good at it. I have worked in the production department at Novo Nordisk. With quality and production.
- ·1 päivä sittenBioporte is weighed down by kidney test recall even though sales are growing We will probably get more information about that later today at 14:00 when there is a webcast https://www.nordnet.dk/markedet/nyheder/9133ec5e-5820-4d73-9b90-90768671459e
- ·1 päivä sittenIn 12 min, 332 kr. has been traded. I wonder if everyone is sitting ready and waiting for the financial report tonight? It's unsettling that a recall of +30 % of quarterly revenue doesn't give rise to a single critical remark.I am on bioporto's mailing list and I have not received news about that recall or seen news about it elsewhere. But I think investment-trade must be a trusted employee and insider since he is the only one who has received the news about it.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 20.8. | ||
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 |
2026 Q2 -tulosraportti
1 päivä sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 20.8. | ||
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·48 min sittenDNB Carnegie's comment on Q2 2026: "Validation trial on track; KDIGO next catalyst – H1 review H1 earnings missed our forecasts as effects from the product recall were above our expectations, but we focus on the ProNephro US adult validation study, which we see as on track for a data readout in H2 2027. Fair value range of DKK0.5–3.0 per share reiterated. H1 review – solid execution and estimate changes. H1 sales were ~3% below our forecast (~14% above adjusted for the DKK2.8m negative impact from the product recall). In our view, this suggests a solid underlying trend in NGAL sales. Reported EBIT was DKK16m including effects from the sale of the antibodies business, offsetting negative effects from the recall. Full- year guidance was maintained but we cut our 2026e adj. EPS by ~15% due to higher opex, while raising 2027–28e by 5–6% on higher gross margin assumptions, driven by sales mix. Adult US ProNephro validation trial on track. BioPorto and the FDA aligned on the US adult validation study design earlier this year, expanding the study size to ~900 patients (~500 in the cut-off study). The first US clinical site was activated on 18 August. Thus, we believe the clinical trial (NCT07751913) remains well on track with expected readout in H2 2027. KDIGO guidelines likely the next catalyst. We expect a decision on KDIGO guidelines for NGAL biomarker tests as early as Q4 2026. Based on KDIGO’s public acute kidney injury (AKI) review, we still consider inclusion as likely, which in our view would provide validation of ProNephro and support broader clinical adoption. ProNephro is already FDA approved for paediatric use, CE-marked internationally, and globally available for RSUO, while we expect adult FDA approval in 2027. For the adult indication alone, we apply a 90% probability of approval and forecast a 27.9% CAGR (2028–45e), with a risk-adjusted NPV of DKK1.8 per share. Fair value range of DKK0.5–3.0 per share reiterated, based on a risk-adjusted SOTP NPV (16.5% WACC, 1.4x beta and 5% liquidity premium): the upper end reflects an additional 10% annual revenue growth and 1% annual EBITDA margin expansion from our forecasts over 2026– 45; the lower end assumes no FDA approval of ProNephro for adults.
- ·21 t sittenWatch or rewatch today's Webcast. https://www.inderes.dk/videos/bioporto-praesentation-af-h1-2026-resultaterYesterday we received news that Bioporto has already gained 54 new customers. Based on what CB said, he believed that the remaining 11 hospitals to be used for research were to be found among these 54 hospitals. It is a question of whether they can agree on the conditions for the hospitals to participate in the research. This is good news, because now there is a chance that they can start the research itself quickly. Bioporto received fast track status last time when the children's test was to be approved, and I hope that Bioporto will apply for it this time too, and get it. Because one of the advantages of this status is that when the FDA finally has to approve the test, it will at most only take 6 months; if one does not have any status, this process will take 10 months. Even better if it is Breakthrough Therapy, but it is rare for this status to be granted.
- ·23 t sittenI think the financial report - really! - holds the course. There has been a rather large product recall. That surprises me based on the following: - Why is the production control not in order? - Why do they produce in such large batches? With a price of 3 million: Do they only produce 8-10 times a year?! That is stupid!!!! I found it difficult to understand today's announcement based on the formulations in the financial report, and I haven't "picked up" the information either. 3D neither, and that says something! BioPorto is in a positive development, but they really need to be careful not to return to the PME-tiden. This financial report is ACCEPTED. But the grade is 4! The communication is simply not good enough! I hope they learn from it. Regards. Bagerbrød (who has kept his shares).Bagerbrød, now I have seen the webcast and I believe that I can tell you why they have started to have large batches. The reason is simple, because they have gained many customers, and therefore they must be able to cover the demand. Regarding the fact that they themselves found out that there are errors in their production so early, is actually also a success. Because it shows that their sample extractions and quality checks also work. As well as the staff at Bioporto who have these tasks, take their job seriously and they are good at it. I have worked in the production department at Novo Nordisk. With quality and production.
- ·1 päivä sittenBioporte is weighed down by kidney test recall even though sales are growing We will probably get more information about that later today at 14:00 when there is a webcast https://www.nordnet.dk/markedet/nyheder/9133ec5e-5820-4d73-9b90-90768671459e
- ·1 päivä sittenIn 12 min, 332 kr. has been traded. I wonder if everyone is sitting ready and waiting for the financial report tonight? It's unsettling that a recall of +30 % of quarterly revenue doesn't give rise to a single critical remark.I am on bioporto's mailing list and I have not received news about that recall or seen news about it elsewhere. But I think investment-trade must be a trusted employee and insider since he is the only one who has received the news about it.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt